YD Bio Limited income statement YDESW

Annual Quarterly

In fiscal 2025, which ended Dec 31, 2025, YD Bio Limited reported revenue of $596,817. It recorded a net loss of $8.3 million. The operating loss came to $5.3 million, an operating margin of -883.3%. Diluted earnings per share were -$0.12.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
Revenue
1
Cost of revenue
0
Gross profit
0
Research and development
2
Selling, general and administrative
4
Operating income
-5
Other income (expense)
-3
Pretax income
-8
Income tax
-0
Net income
-8
Basic EPS
-0.12
Diluted EPS
-0.12
Weighted average shares, basic
67
Weighted average shares, diluted
67
Other measures
Depreciation and amortization
0
EBITDA
-5
Interest coverage
-6,828.65x
Margins
Gross margin
28.05%
Operating margin
-883.31%
Pretax margin
-1,392.86%
Profit margin
-1,392.61%
EBITDA margin
-880.58%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Services-Medical Laboratories (SIC 8071)
Listed as
YDES (Nasdaq), YDESW (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Taipei City
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
2011674
Former names
True Velocity, Inc./DE (until Jun 21, 2024)

Other Services-Medical Laboratories companies

All 29 Services-Medical Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.